Differentiated high-grade thyroid carcinoma (DHGTC) is a new entity in the 2022 WHO
classification. We aimed to investigate the incidence and clinicopathological features of …

Background: Poorly differentiated thyroid carcinoma (PDTC) has an intermediate prognosis
between indolent well-differentiated thyroid carcinoma (TC) and anaplastic carcinoma …

Thyroid carcinoma of follicular cell origin exists on a histopathologic and clinical spectrum.
On one end, up to 87% of thyroid cancers are well-differentiated and have a very favorable …

Background Differentiated high‐grade thyroid carcinoma (DHGTC) is recently recognized by
the World Health Organization (WHO) as a subgroup of thyroid carcinomas with high‐grade …

Background Differentiated high-grade thyroid carcinomas (DHGTCs) are a new diagnostic
entity most recently defined in the 2022 World Health Organization's (WHO) Classification of …

Background Poorly differentiated thyroid carcinoma (PDTC) is a distinct entity with
intermediate prognosis between indolent follicular thyroid cancers and anaplastic …

The classification of thyroid nodules, particularly those with a follicular growth pattern, has
significantly evolved. These tumors, enriched with RAS or RAS-like mutations, remain …

Thyroid carcinomas are the most common endocrine malignancy and commonly have
alterations in the mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 …

Background and Objectives: The ki67 nuclear protein is a tool for diagnosis and prognosis in
oncology that is used to evaluate cell proliferation. Differentiated thyroid carcinoma is …

Differentiated high-grade thyroid carcinoma (DHGTC) is a new subset within the spectrum of
thyroid malignancies. This review aims to provide a comprehensive overview of DHGTC …